

February 24, 2025

Dear Pharmaceutical Manufacturer:

Arizona's Medicaid Program, the Arizona Health Care Cost Containment System (AHCCCS), has contracted with Prime Therapeutics to secure supplemental rebates for preferred agents on the AHCCCS Drug List. The AHCCCS Drug List is utilized by both the Fee-For-Service and Managed Care Organization (MCO) programs.

AHCCCS intends to obtain rebates on both Fee-For-Service and Managed Care utilization for preferred agents listed on the AHCCCS drug list which is managed by AHCCCS. The drug list contains CMS Covered Outpatient Drugs that are dispensed to persons enrolled in Medicaid, the Children's Health Insurance Program and to persons with Serious Mental Illness, as defined in A.R.S. 36-550, who qualify for state funded care under A.R.S. 36-3408. The AHCCCS supplemental rebate agreements are drafted with the express purpose of establishing a single preferred drug list and described further in section 2.1 of the ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM SUPPLEMENTAL DRUG-REBATE AGREEMENT (SRA), that was approved by CMS on May 28, 2015.

SRA 2.1 It is the intent of this Agreement that the State will receive Supplemental Rebates, in addition to the rebates received under Manufacturer's CMS Agreement, pursuant to Section 1927 of the Social Security Act (42 U.S.C. §1396r-8), for the Manufacturer's Supplemental Covered product(s) quarterly utilization in the Arizona Medicaid Program, including all Fee-For-Service and Managed Care beneficiaries, in which there is Medicaid federal financial participation. The parties also intend for this Agreement to meet the requirements of federal law at Section 1927 of the Social Security Act (42 U.S.C. §1396r-8).

The next P&T Meeting is scheduled for May 21, 2025. The meeting will be held virtually and is scheduled to begin at Noon and end at 5 PM.

At this time, supplemental rebate offers are requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee:

- Analgesics, Long-Acting Narcotic
- Antibiotics, Inhaled
- Antimigraine Agents, Other
- Antipsychotics, Atypical Long-Acting Injectable
- Antipsychotics, Oral Atypical (2nd Gen Only)
- Colony Stimulating Factors
- COPD Agents
- Cystic Fibrosis
- Cytokine and CAM Antagonists
- Glucagon Agents
- Glucocorticoids, Inhaled
- Growth Hormone
- Hepatitis C Agents
- HIV AIDS
- Hyperoxaluria Treatments
- Hypoglycemics (Insulin and Related Agents)
- Hypoglycemics, Incretin Mimetics/Enhancers
- Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)
- Movement Disorders
- Multiple Sclerosis Agents
- Opioid Dependence Treatments
- Pancreatic Enzymes
- Stimulants and Related Agents

New Drug Reviews

1. Alyftrek
2. Crenessity
3. Tryngolza
4. Tryvio

Manufacturer representatives and the public may use the link below to submit a request to provide oral or written testimony for medications listed under New Drug Reviews above and also for drugs listed in the supplemental rebate therapeutic classes. Submitting public testimony shall be in accordance with the AHCCCS P&T Operational Policy which can be located under Arizona on the Prime Therapeutics website. A link to the Prime Therapeutics Government Solutions web page is provided below:

<https://www.primetherapeutics.com/en/single-state-programs>

We look forward to you attending the virtual AHCCCS P&T Committee Meeting on May 21, 2025.

Sincerely,



Carmen Heredia
Director